MONTCLAIR, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced today the release of a company overview as presented by FluoroPharma's President, CEO and Chairman of the Board, Thijs Spoor. This second \"State of the Union\" address serves to provide shareholders with a perspective on the company, its evolution and future potential. <\/p>\n
Mr. Spoor began the communication by stating, \"Our company vision is clear, our financial position is sound, our promising product portfolio is on track and our company is led by a highly qualified team with significant and directly applicable experience in the successful development of radiopharmaceuticals. Our comprehensive technology platform was developed by scientists at the Massachusetts General Hospital and we are well positioned to capitalize on its superior technology.\" <\/p>\n
\"As we advance our business model, we recognize the importance of keeping shareholders informed, and it is with this intention that I present this to you today.\" <\/p>\n
Our Business Outlook <\/p>\n
FluoroPharma is looking to capitalize on the growth of PET in cardiac diagnostics. In development are three novel cardiac PET radiopharmaceuticals, two of which are in clinical-stage and have advanced to phase II clinical. The third candidate is in the pre-clinical, early development stage. <\/p>\n
FluoroPharma's products are aimed at improving overall patient care via improved disease detection and could potentially provide greater diagnostic accuracy compared to currently employed nuclear imaging agents and modalities, increase the use of PET in cardiac imaging, and help reduce the number of unnecessary diagnostic and therapeutic procedures. <\/p>\n
In the U.S., there are estimated to be more than 2 million PET imaging procedures done per year according to Biotech Systems -- although the vast majority of these scans are for the diagnosis of cancer. PET is becoming more established in the cardiac setting as several factors have led to a shift in favor of PET for the diagnosis of cardiac disease. <\/p>\n
Roughly one-third of all Americans are estimated to have some form of cardiovascular disease, with approximately 13 million people suffering from coronary artery disease. Cardiovascular disease is the number one leading cause of death in the U.S., claiming almost one million lives per year. People with cardiovascular disease typically have an accumulation of plaque within the walls of the coronary arteries (i.e. - atherosclerosis) that supply the myocardium (heart muscle) with oxygen. Known as coronary artery disease (CAD), the condition is progressive and can result in severely reduced supply of blood to the heart (i.e. - myocardial ischemia or ischemic heart disease). Acute coronary syndrome (ACS) is a term used to describe symptoms of the disease, such as chest pain or a heart attack. As these symptoms may not be present until the disease has progressed to an advanced stage, barring a reliable diagnosis and appropriate intervention, CAD is often fatal. Cardiac imaging is used to diagnose CAD and to determine the presence and severity of ischemic heart disease and the related risk of suffering a heart attack. It is also used to help determine the most appropriate course of treatment. <\/p>\n
Our Portfolio <\/p>\n
FluoroPharma's initial focus is the development of innovative positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). The FluoroPharma team is advancing two products in clinical trials for the assessment of cardiac disease. These first in class novel diagnostic agents have been designed to rapidly target myocardial cells. Other products in the pipeline include imaging agents for detection of a bio-marker associated with Alzheimer's disease and imaging agents that could potentially be used for imaging specific cancers. <\/p>\n<\/p>\n
Follow this link:<\/p>\n
FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" MONTCLAIR, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced today the release of a company overview as presented by FluoroPharma's President, CEO and Chairman of the Board, Thijs Spoor. Continue reading